Published in Gene Therapy Weekly, September 28th, 1998
And as more U.S. patients buy more of the therapies - and thus live longer to buy even more - the market will keep growing for at least the rest of the decade, according to a new report by Datamonitor, a New York-based independent strategic management consultancy specializing in the analysis of global healthcare companies and their markets.
"The cost of maintaining patients using combination therapies will therefore increase as more people need the therapies longer," said Datamonitor analyst Patrick Taaffee. "Resistance to drugs is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.